About Our Company
Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP™ Technology to design peptides and peptide mixtures.
Meet Our Team
Kathy Collins
Manager, Immunoassay Development
Kathy Collins joined Peptimmune in 2004 as a leader in Immunoassay Development, with over 20 years of experience in immunology and assay development. Before joining Peptimmune, Kathy was at BiogenIdec in Analytical…
